Sulfonic acid and aldehyde condensation polymers for the treatment and prevention of HPV
View Patent ↗The present invention relates to a method of treating and preventing a papillomavirus infection in an individual, comprising administering to the individual a therapeutically effective amount of a condensation polymer of an aromatic sulfonic acid and an aldehyde, or a pharmaceutically acceptable salt thereof.
1. A method of inactivating a papillomavirus infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a condensation polymer of formula (III):
or a pharmaceutically acceptable salt thereof, wherein n is about 21.
2. The method according to claim 1 , wherein the papillomavirus is human papillomavirus (HPV).
3. The method of claim 1 , wherein the polymer is administered intravaginally, rectally or on genitalia.
4. The method of claim 1 , wherein the condensation polymer is administered in a physiologically acceptable carrier.
5. The method of claim 4 , wherein the physiologically acceptable carrier is a formulation selected from a gel, cream, and foam.
6. The method of claim 5 , wherein the formulation is a gel.
7. The method of claim 5 , wherein the condensation polymer is present in the formulation in a concentration between about 0.05% and about 10% by weight.
8. The method of claim 7 , wherein the condensation polymer is present in the formulation in a concentration between about 0.1% and about 7% by weight.
9. The method of claim 8 , wherein the condensation polymer is present in the formulation in a concentration of about 0.5% or about 2% by weight.
10. A method of treating a papillomavirus infection in a papillomavirus-infected individual in need thereof, comprising administering to the individual a therapeutically effective amount of a condensation polymer of formula (III):
or a pharmaceutically acceptable salt thereof, wherein n is about 21.
11. The method according to claim 10 , wherein the papillomavirus is human papillomavirus (HPV).
12. The method of claim 10 , wherein the condensation polymer is administered intravaginally, rectally, or on genitalia.
13. The method of claim 10 , wherein the condensation polymer is administered in a physiologically acceptable carrier.
14. The method of claim 13 , wherein the physiologically acceptable carrier is a formulation selected from a gel, cream, and foam.
15. The method of claim 14 , wherein the formulation is a gel.
16. The method of claim 14 , wherein the condensation polymer is present in the formulation in a concentration between about 0.05% and about 10% by weight.
17. The method of claim 16 , wherein the condensation polymer is present in the formulation in a concentration between about 0.1% and about 7% by weight.
18. The method of claim 17 , wherein the condensation polymer is present in the formulation in a concentration of about 0.5% or about 2% by weight.
19. A method of inactivating a papillomavirus infection in an individual in need thereof, comprising contacting the papillomavirus or warts caused by papillomavirus infection with a therapeutically effective amount of a condensation polymer of formula (III):
or salt thereof, wherein n is about 21.